Breaking News
5311 - 5325 of 6609 results
Prev
353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441
Next
September 28, 2007
Bernard Poussot has been appointed president and chief executive officer, Wyeth, effective January 1, 2008. He replaces Robert Essner, who will continue as chairman of the board of directors for the transition period.
Mr. Poussot joined the co…
Read More »
September 28, 2007
Novartis and the Massachusetts Institute of Technology (MIT) have entered a 10-year research collaboration with the goal of transforming the pharmaceutical production process.
The partnership, known as the Novartis-MIT Center for Continuous Manufa…
Read More »
September 28, 2007
Celera, an Applera Corp. business, earned a $2 million clinical milestone payment from Merck & Co. under the two companies cathepsin K inhibitor collaboration agreement.
This payment recognizes Merck's advancement of odanacatib (formerly MK-…
Read More »
September 28, 2007
Patrick M. Sullivan has been named vice president of R&D for the Research Biotech business unit of Sigma-Aldrich. In this role, he will help expand the company's leadership position through the development of new and innovative products for life…
Read More »
September 27, 2007
PAREXEL International Corp. has completed the acquisition of Taiwan-based APEX International Clinical Research Co., Ltd. for approximately $51 million. The acquisition adds to PAREXEL's clinical research service offerings in the Asia-Pacific region,…
Read More »
September 27, 2007
Galapagos NV and ProStrakan Group achieved the third milestone under Galapagos' collaboration with Novartis in antibodies for bone-related diseases. This milestone triggers a payment of $1.5 million to Galapagos, of which Galapagos will pay $1.1 mill…
Read More »
September 27, 2007
SAFC will invest $29 million to expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel. The site expansion will allow SAFC Pharma to provide process development and cGMP manufacturing for l…
Read More »
September 26, 2007
Baxter BioPharma Solutions recently completed the lyophilization capacity expansion at their cytotoxic contract manufacturing facility in Halle, Germany. The expansion increased their total cytotoxic lyophilization capacity to four dedicated lyophili…
Read More »
September 26, 2007
Genzyme Corp. and Bayer Schering Pharma AG began the first of two planned Phase III trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).
The CARE-MS I trial (Comparison of Alemtuzumab and Rebif Ef…
Read More »
September 25, 2007
Bristol-Myers Squibb has signed a definitive agreement to acquire Adnexus Therapeutics for $430 million in cash. Adnexus has developed a new therapeutic class of biologics called Adnectins, which BMS plans to use to advance its biologics strategy in…
Read More »
September 25, 2007
GlaxoSmithKline has licensed MedImmune's reverse genetics technology for the development of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics allows manufacturers to avoid working directly with the infectious, circula…
Read More »
September 25, 2007
DSM Venturing, the corporate unit of Royal DSM N.V., has made an equity investment in Upfront Chromatography, a developer of customized industrial protein chromatography processes. According to DSM, Upfront's downstream processing platform has the po…
Read More »
September 24, 2007
Verus Pharmaceuticals, Inc. sold its pediatric asthma development programs to AstraZeneca. This includes the North American rights to a Captisol enabled budesonide solution (controller medication), a short-acting beta agonist solution (rescue medicat…
Read More »
September 24, 2007
Array BioPharma and Celgene Corp. entered a strategic R&D collaboration focused on novel therapeutics in cancer and inflammation. Under the agreement, Array will receive an upfront payment of $40 million and will grant Celgene an option to select…
Read More »
September 24, 2007
Pfizer received approval from the European Commission (EC) for Celsentri (maraviroc) for treatment-experienced HIV patients. Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients…
Read More »
5311 - 5325 of 6609 results
Prev
353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441
Next
